Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 6/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MAP2 | P11137 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102790 | 0.98 | PDK2 (0.40) | PDK2TNFDHODHALOX5PIK3CD | |
| SCHEMBL1102613 | 0.98 | PDK2 (0.40) | PDK2TNFDHODHALOX5PIK3CD | |
| SCHEMBL1102629 | 0.96 | PDK2 (0.39) | PDK2TNFDHODHALOX5PIK3CD | |
| SCHEMBL1102593 | 0.96 | PDK2 (0.42) | PDK2TNFDHODHALOX5PIK3CD | |
| SCHEMBL1102682 | 0.96 | PDK2 (0.38) | PDK2TNFDHODHPIK3CD | |
| SCHEMBL1102795 | 0.95 | TNF (0.39) | PDK2TNFALOX5PIK3CDMAP2 | |
| SCHEMBL1102813 | 0.95 | PDK2 (0.39) | PDK2TNFDHODHALOX5PIK3CD | |
| SCHEMBL1102894 | 0.95 | PDK2 (0.39) | PDK2TNFDHODHALOX5PIK3CD | |
| SCHEMBL1102587 | 0.94 | PDK2 (0.40) | PDK2TNFALOX5PIK3CDMAP2 | |
| SCHEMBL1103641 | 0.94 | PDK2 (0.38) | PDK2TNFDHODHALOX5PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190319194-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| US-20160149139-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160149139-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160104847-A1 | NOVEL COMPOUNDS AND USES IN DEVICES | UNIVERSAL DISPLAY CORPORATION | 2016-04-14 | — | — | US | disclosed |
| US-20160104847-A1 | NOVEL COMPOUNDS AND USES IN DEVICES | UNIVERSAL DISPLAY CORPORATION | 2016-04-14 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| EP-2147962-A1 | Azaanthracene-derivatives and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | PDK2 1930/4885TNF 3803/4885DHODH 1013/4885 |
| US-20160104847-A1 | NOVEL COMPOUNDS AND USES IN DEVICES | TERT, UACA, TXN | PDK2 3633/4885TNF 241/4885DHODH 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.